Google
Trusted Resources: News & Events
Latest announcements and gatherings
MARAC Advisory Statement: Gene Therapy & Bone Marrow Therapies
Please note: A previous version of this advisory incorrectly stated that MARAC is aware of three cases of leukemia and other cancer-like conditions in patients who have undergone gene therapy. MARAC is only aware of two such cases. The below statement has been updated accordingly.
May 15, 2021 – The Sickle Cell Disease Association of America’s Medical and Research Advisory Committee is aware of two cases of leukemia or other cancer-like conditions in people who have undergone gene therapy for sickle cell disease. This is more than would be expected given the small number of individuals who have undergone gene therapy to date. It is unclear why cancer developed in these individuals. The mission of SCDAA is to promote the best interests of individuals living with SCD. Accordingly, SCDAA MARAC urges action in three directions:
1. Informing patients, families and others about the current understanding of cancer risk as it pertains to sickle cell disease in a clear and accurate way.
- Educate individuals with SCD who are participating in gene therapy (gene editing as well as lentiviral gene transfer) and other stem cell transplants (bone marrow therapies). Ensure that the consent forms reflect the recent findings and potential risks of leukemia and MDS.
- Educate the greater SCD community by providing cancer risk estimates in the general population of individuals with SCD treated with other types of therapies.
- Enlist experts in cancer genetic risk communication (e.g., NCI) and SCD stakeholders to develop education about risks of cancer in SCD.
2. Funding for research to better understand and address cancer-related risks of gene therapy and stem cell transplant (bone marrow therapies) in sickle cell disease.
- Understand whether sickle cell disease intrinsically involves an increased risk of cancer; and, if so, what causes the increased risk.
- Identify people living with sickle cell disease who are at increased risk for the development of cancer as they undergo “bone marrow therapies.”
- Identify components of “bone marrow therapies” that increase risk of cancer.
- Bring together scientific experts from the fields of SCD, cancer, stem cell transplant and gene therapy to answer these questions.
3. Funding for and creation of a way to collect information about cancer-related risks from all studies that involve “bone marrow therapies” for sickle cell disease globally.
+myBinderRelated Content
-
Pioneering a New Therapy for Sickle Cell DiseaseThe science behind sickle cell disease (...
-
CRISPR could end sickle cell disease, but signing up black patients for clinical trials will be a hard sellThe first attempts to use a groundbreaki...
-
SCDAA News Advisory: Partial Hold on Gene Therapy TrialOn December 20, the FDA placed a partial...
-
Nutritional Status, Nutrient Intake, and Food Diversity Among Children With Sickle Cell AnemiaChildren with sickle cell anemia (SCA) o...
-
Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow TransplantObjective: A comparative cost analysis o...
-
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
-
Patient Perspective: Childhood Experiences of Sickle Cellhttps://www.youtube.com/watch?v=982zM-s4...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.